Published in Histopathology on August 21, 2007
Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer (2010) 3.84
Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol (2009) 1.84
The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther (2009) 1.78
Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta (2010) 1.58
Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genomics (2008) 1.45
Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology (2010) 1.31
Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. Int J Mol Sci (2013) 1.28
Microtubules and their role in cellular stress in cancer. Front Oncol (2014) 1.15
Class III beta-tubulin is a component of the mitotic spindle in multiple cell types. J Histochem Cytochem (2008) 1.09
Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation. J Biol Chem (2011) 1.07
Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass. Clin Sci (Lond) (2015) 0.94
Increased levels of a unique post-translationally modified betaIVb-tubulin isotype in liver cancer. Biochemistry (2008) 0.90
βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget (2015) 0.90
MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. J Cell Mol Med (2013) 0.81
High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer. Clin Breast Cancer (2012) 0.81
Characterization of a human βV-tubulin antibody and expression of this isotype in normal and malignant human tissue. Cytoskeleton (Hoboken) (2012) 0.79
Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy. PLoS One (2015) 0.78
Induction of neural differentiation in rat C6 glioma cells with taxol. Brain Behav (2015) 0.77
Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. Neoplasia (2016) 0.75
Comparative proteomic analysis of paclitaxel resistance-related proteins in human breast cancer cell lines. Oncol Lett (2016) 0.75
Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. Oncol Lett (2017) 0.75
An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance. Int J Mol Sci (2017) 0.75
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg (1997) 8.86
Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg (2001) 8.34
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med (2000) 6.27
Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg (1995) 5.66
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg (1996) 5.42
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg (1997) 3.90
Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg (1991) 3.88
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res (2000) 3.74
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med (2000) 3.70
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant (1996) 3.51
Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology (2001) 3.38
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res (1998) 2.89
p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res (1997) 2.88
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res (1994) 2.80
Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg (2001) 2.80
Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol (2000) 2.63
Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg (1998) 2.60
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59
Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg (1997) 2.53
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50
Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. Carcinogenesis (2006) 2.45
Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res (2000) 2.40
Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg (1999) 2.36
K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res (1996) 2.29
Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res (1994) 2.26
Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res (1998) 2.23
Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res (1987) 2.14
Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol (2000) 2.12
Allelotype of pancreatic adenocarcinoma. Cancer Res (1994) 2.11
The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res (1993) 2.05
Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am (1998) 2.03
Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst (1999) 2.03
Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg (2000) 2.00
Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res (2001) 1.98
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res (1998) 1.97
Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res (2001) 1.96
Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst (2000) 1.94
Immortalization with telomerase of the Nestin-positive cells of the human pancreas. Biochem Biophys Res Commun (2003) 1.93
Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer (2008) 1.93
STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol (2001) 1.89
A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant (1991) 1.87
Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut (2008) 1.82
Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol (2000) 1.81
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther (2005) 1.79
Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol (1994) 1.79
CT evaluation of amyloidosis: spectrum of disease. Radiographics (1993) 1.77
Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res (1996) 1.75
BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol (2000) 1.72
CT and MR imaging of benign hepatic and biliary tumors. Radiographics (1999) 1.71
DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol (1998) 1.71
Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol (2000) 1.69
Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res (1994) 1.68
Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg (1996) 1.67
Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst (1991) 1.64
Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol (1999) 1.59
Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol (1998) 1.59
Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol (1994) 1.59
Association of duration of television viewing in early childhood with the subsequent development of asthma. Thorax (2009) 1.59
Peritransplant injury to the myocardium associated with the development of accelerated arteriosclerosis in heart transplant recipients. Am J Surg Pathol (1994) 1.58
Cystadenomas of the pancreas: is enucleation an adequate operation? Ann Surg (1998) 1.58
Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol (1996) 1.57
The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol (1998) 1.56
Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy. Ann Surg (1991) 1.55
Should pancreaticoduodenectomy be performed in octogenarians? J Gastrointest Surg (1999) 1.53
Familial pancreatic cancer. Cancer J (2001) 1.51
The autopsy: still important in cardiac surgery. Ann Thorac Surg (1997) 1.50
Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res (2001) 1.49
Progression of esophageal carcinoma by loss of EGF-STAT1 pathway. Cancer J (2001) 1.49
Carcinoma of the body and tail of the pancreas. Am J Surg (1992) 1.48
Allelotype of head and neck squamous cell carcinoma. Cancer Res (1994) 1.47
5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res (2001) 1.46
Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol (2001) 1.46
Abnormal air-filled spaces in the lung. Radiographics (1993) 1.45
Spectrum of cystic tumors of the pancreas. Am J Surg (1992) 1.45
Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res (1995) 1.45
Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res (2000) 1.43
Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol (1998) 1.42
Hyperplastic, preneoplastic and neoplastic lesions found in 83 human pancreases. Am J Clin Pathol (1982) 1.42
Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res (2001) 1.40
Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg (1999) 1.40
Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res (1994) 1.40
Krukenberg tumors: CT features and growth characteristics. South Med J (1989) 1.39
Adenocarcinoma of the duodenum: factors influencing long-term survival. J Gastrointest Surg (1999) 1.38
Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev (1998) 1.36
Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm (2000) 1.35